The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain.
Recently, we reported the real-world effectiveness of palbociclib plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC) in Japan (NCT05399329). However, median overall survival (OS) was not reached because of limited follow-up (36 months). Here, we present follow-up data from this study, including real-world clinical outcomes and treatment patterns.
Since 2021, additional real-world evidence (RWE) has emerged on the effectiveness of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line treatment of HR-positive/HER2-negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC), necessitating this updated review.
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician’s choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician’s choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)–positive locally advanced/metastatic breast cancer (LA/mBC).
Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 − advanced breast cancer (ABC). We report efficacy, safety, and patient-reported outcomes (PROs) across age groups, including older patients, in these trials.
This study further explored patient-reported health-related quality of life (HRQOL), functioning, symptoms, and symptom tolerability in CAPItello-291.
In this Review, we describe key steps in the development of the modern paradigm for the treatment of HER2-positive advanced-stage breast cancer, including selecting and sequencing new-generation HER2-targeted therapies, and summarize efficacy and safety outcomes from pivotal studies.
2024 Research Article Collection A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients living with Breast Cancer. Filter by TopicDetection & Diagnoses of Breast CancerPain Management / Multidisciplinary TeamTherapeutic Options & Guidelines Comprehensive Pain Management: The Role of the Multidisciplinary Team, Shared Decision-Making, and Patient Access
2024 Research Article Collection Read More »
Integrating Novel Therapeutics and Personalised Care A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients living with Breast Cancer. Filter by Topic2025 CollectionAbemaciclibAdjuvant TherapyAlpelisib-fulvestrantAntibody-Drug ConjugateAsia-PacificBevacizumabBRCA1/2Breast SurgeryCapivasertibCDK4/6 inhibitorCDK4/6iChemotherapyClinical TrialClinical TrialsCommunicationDalpicilibDiagnosisEarly Breast CancerEndocrine TherapyER+/HER2- Advanced Breast CancerER+/HER2− breast cancerESMOFollow-upFulvestrantGuidelineGuidelinesHER2- Low Metastatic Breast CancerHER2-low MBCHER2+ Breast CancerHER2+ Early Breast
Integrating Novel Therapeutics and Personal Care Read More »
This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.
